Disease management improves end-stage renal disease outcomes

被引:2
|
作者
Sands, Jeffrey J. [1 ]
机构
[1] Fresenius Med Care, Celebration, FL 34747 USA
关键词
disease management; end-stage renal disease; hemodialysis; cost control;
D O I
10.1159/000093682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Renal disease management organizations have reported achieving significant decreases in mortality and hospitalization in conjunction with cost savings, improved patient satisfaction and quality of life. Disease management organizations strive to fill existing gaps in care delivery through the standardized use of risk assessment, predictive modeling, evidence-based guidelines, and process and outcomes measurement. Patient self-management education and the provision of individual nurse care managers are also key program components. Methods:As we more fully measure clinical outcomes and total healthcare costs, including payments from all insurance and government entities, pharmacy costs and out of pocket expenditures, the full implications of disease management can be better defined. Results: The results of this analysis will have a profound influence on United States healthcare policy. Conclusion: At present current data suggest that the promise of disease management, improved care at reduced cost, can and is being realized in end-stage renal disease. Copyright (c) 2006 S. Karger AG, Basel
引用
下载
收藏
页码:394 / 399
页数:6
相关论文
共 50 条
  • [41] Epidemiology of end-stage renal disease
    Roderick, P
    CLINICAL MEDICINE, 2002, 2 (03) : 200 - 204
  • [42] End-stage renal disease in leprosy
    Lomonte, C
    Chiarulli, G
    Cazzato, F
    Giammaria, B
    Marchio, G
    Losurdo, N
    Antonelli, M
    Casucci, F
    Basile, C
    JOURNAL OF NEPHROLOGY, 2004, 17 (02) : 302 - 305
  • [43] HYPERTENSION IN END-STAGE RENAL DISEASE
    PAGE, LB
    NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (18): : 1018 - &
  • [44] Adiponectin and end-stage renal disease
    Markaki A.
    Psylinakis E.
    Spyridaki A.
    Hormones, 2016, 15 (3) : 345 - 354
  • [45] Silicosis and end-stage renal disease
    Steenland, K
    Rosenman, K
    Socie, E
    Valiante, D
    SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH, 2002, 28 (06) : 439 - 442
  • [46] Lipids in end-stage renal disease
    Wanner, C
    JOURNAL OF NEPHROLOGY, 2002, 15 (02) : 202 - 204
  • [47] Osteoporosis in end-stage renal disease
    Lindberg, JS
    Moe, SM
    SEMINARS IN NEPHROLOGY, 1999, 19 (02) : 115 - 122
  • [48] Keloids and end-stage renal disease
    Freedman, BI
    Morrow, MA
    Tuttle, AB
    Igwemezie, BM
    Rich, SS
    Sherertz, EF
    Tuttlea, FNAJANAEB
    NEPHRON, 1998, 80 (02): : 244 - 246
  • [49] Adiponectin and end-stage renal disease
    Markaki, Anastasia
    Psylinakis, Emmanuel
    Spyridaki, Aspasia
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (03): : 345 - 354
  • [50] Hypertension in end-stage renal disease
    Martínez-Maldonado, M
    KIDNEY INTERNATIONAL, 1998, 54 : S67 - S72